Acta dermato-venereologica · 2019
Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hardy Juliette, Boralevi Franck, Mallet Stéphanie, Cabrera Natalia, Belot Alexandre, Phan Alice, Barbarot Sébastien, Duriez-Lasek Audrey, Chiaverini Christine, Hubiche Thomas, Mahé Emmanuel, Bégon Edouard, Bourrat Emmanuelle, Boccara Olivia, Aubert Hélène, Lerosey Martine Grall, Droitcourt Catherine, Piram Maryam, Mazereeuw-Hautier Juliette, Research Group of the French Society of Paediatric Dermatology (SDFP in French)
Аннотация
Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho-trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho-trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho-trexate and we did not identify a clinical profile for those resistant patients.